Last reviewed · How we verify

Atazanavir/ Stavidine / Lamivudine

Bristol-Myers Squibb · FDA-approved active Small molecule

Atazanavir/ Stavidine / Lamivudine is a Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) Small molecule drug developed by Bristol-Myers Squibb. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients. Also known as: Reyataz.

This combination inhibits HIV replication by blocking reverse transcriptase and protease enzymes required for viral reproduction.

This combination inhibits HIV replication by blocking reverse transcriptase and protease enzymes required for viral reproduction. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.

At a glance

Generic nameAtazanavir/ Stavidine / Lamivudine
Also known asReyataz
SponsorBristol-Myers Squibb
Drug classAntiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)
TargetHIV protease, HIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

Atazanavir is a protease inhibitor that prevents HIV protease from cleaving viral polyproteins, while stavudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block the reverse transcriptase enzyme needed to convert HIV RNA into DNA. Together, these three agents target different steps of the HIV replication cycle to suppress viral load.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Atazanavir/ Stavidine / Lamivudine

What is Atazanavir/ Stavidine / Lamivudine?

Atazanavir/ Stavidine / Lamivudine is a Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) drug developed by Bristol-Myers Squibb, indicated for HIV-1 infection in treatment-naïve and treatment-experienced patients.

How does Atazanavir/ Stavidine / Lamivudine work?

This combination inhibits HIV replication by blocking reverse transcriptase and protease enzymes required for viral reproduction.

What is Atazanavir/ Stavidine / Lamivudine used for?

Atazanavir/ Stavidine / Lamivudine is indicated for HIV-1 infection in treatment-naïve and treatment-experienced patients.

Who makes Atazanavir/ Stavidine / Lamivudine?

Atazanavir/ Stavidine / Lamivudine is developed and marketed by Bristol-Myers Squibb (see full Bristol-Myers Squibb pipeline at /company/bristol-myers-squibb).

Is Atazanavir/ Stavidine / Lamivudine also known as anything else?

Atazanavir/ Stavidine / Lamivudine is also known as Reyataz.

What drug class is Atazanavir/ Stavidine / Lamivudine in?

Atazanavir/ Stavidine / Lamivudine belongs to the Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) class. See all Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) drugs at /class/antiretroviral-combination-therapy-protease-inhibitor-nucleoside-reverse-transcriptase-inhibitors.

What development phase is Atazanavir/ Stavidine / Lamivudine in?

Atazanavir/ Stavidine / Lamivudine is FDA-approved (marketed).

What are the side effects of Atazanavir/ Stavidine / Lamivudine?

Common side effects of Atazanavir/ Stavidine / Lamivudine include Hyperbilirubinemia (unconjugated), Nausea, Diarrhea, Headache, Peripheral neuropathy (stavudine-related), Lipodystrophy (stavudine-related).

What does Atazanavir/ Stavidine / Lamivudine target?

Atazanavir/ Stavidine / Lamivudine targets HIV protease, HIV reverse transcriptase and is a Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors).

Related